Testing a new drug called CBX-663 in adults with glioblastoma or other cancers
Original title: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people that mainly looks at safety and dosing.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a new drug, CBX-663, in adults whose cancer came back or kept growing.
Who this trial is for. This trial is for adults 18 and older with one of three cancer types, including glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that has come back or kept growing. It tests the drug CBX-663, given through a vein on day 1 and then once a week in 21-day cycles, at different dose levels.
Where it stands. The trial has not reported results. It is looking at how safe the drug is, how well people handle it, and whether it acts on the cancer. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: This is one of the studies a person with recurrent or progressive glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary might hear about. If that sounds like you, you could ask your care team about it. They can help you weigh it against your other choices.
What it doesn't mean: This does not mean CBX-663 works. A trial is a test, not a proven treatment. Joining one is not a guarantee that it will help you, and it is not a promise of a cure. The trial team decides who can take part.
Source: ClinicalTrials.gov, August 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.